Fulcrum Therapeutics Halts Sickle Cell Drug After FDA Safety Concerns
Event summary
- Fulcrum Therapeutics discontinued its pociredir program for sickle cell disease (SCD) on June 1, 2026, following FDA feedback on safety concerns.
- The FDA's decision was influenced by the withdrawal of Tazverik® (tazemetostat) due to secondary malignancies, raising similar risks for pociredir.
- Fulcrum will explore strategic alternatives, including potential mergers or acquisitions, to maximize shareholder value.
- As of March 31, 2026, Fulcrum had $333.3 million in cash, cash equivalents, and marketable securities.
The big picture
Fulcrum's decision to halt pociredir underscores the regulatory risks associated with developing therapies targeting the PRC2 complex. The move reflects broader industry challenges in balancing innovation with safety concerns, particularly in rare disease treatments. Fulcrum's strategic review will be closely watched as it navigates potential exits or partnerships to offset the loss of its lead program.
What we're watching
- Regulatory Headwinds
- How the FDA's stance on PRC2 inhibitors will impact other biotech firms developing similar therapies.
- Strategic Alternatives
- The pace at which Fulcrum can secure a merger or acquisition deal to preserve shareholder value.
- Financial Stability
- Whether Fulcrum's $333.3 million in cash reserves will be sufficient to sustain operations during the strategic review.